Month: May 2022

Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

Excellent Progress in Pepinemab Clinical Programs Promising responses in Phase 1b segment of the open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC);Phase 2 enrollment underway Enrollment underway in Phase 1/2a study of pepinemab in Alzheimer’s disease ROCHESTER, N.Y., May 16, 2022 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update on key events since the start of 2022. “I am pleased to report that Vaccinex’s clinical programs for oncology and neurodegenerative disease have made substantial...

Franchise Global to Acquire German Pharmaceutical and Medical Cannabis Products Distributor, Strengthening its Position in the German Pharmaceutical and Medical Cannabis Market

Written by Customer Service on May 16, 2022. Posted in Mergers And Acquisitions.

The acquisition is expected to strengthen operations and drive synergies in Germany, a key region of the Company’s growth strategy VANCOUVER, British Columbia , May 16, 2022 (GLOBE NEWSWIRE) — Franchise Global Health Inc. (“Franchise Global” or the “Company“) (TSX‑V: FGH; FRA: WV4A) is pleased to announce that it has entered into a letter of intent (the “LOI“) dated effective May 6, 2022, outlining the general terms and conditions pursuant to which it has agreed to acquire a leading German pharmaceutical distributor (the “Target Company“). Management of Franchise Global expects that the acquisition, if completed, will strengthen the Company’s end-to-end pharmaceutical, medical cannabis operations and infrastructure in Germany, a key market for the Company. Clifford Starke,...

Interim Management Statement covering Q3 2021/22

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

Interim Management Statement covering Q3 2021/22 The Board of Directors of Rovsing A/S has today reviewed and approved the Interim Management Statement for the third quarter (1 January 2022– 31 March 2022) of the financial year 2021/22. Q3 highlightsIn Q3 of the financial year 2021/22, the revenue amounted to DKK 6,8 million (DKK 7,6 million in Q3 2020/21).Q3 EBITDA amounts to DKK 0,2 million (DKK 0,9 million in Q3 2020/21).As highlighted in Announcement 332, the year-to-date performance of the current financial year has been impacted by delays in primarily two large projects, resulting in delayed revenue. The planned activities on the large Galileo 2nd Gen EGSE project are shifted due to delayed incoming Customer requirement updates. In addition, NASA and ESA have announced a 1-year overall postponement of the Mars Sample Return...

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

Presented pre-clinical data at American Association for Cancer Research (AACR 2022), demonstrating GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) driving NK cell activation and ADCC against head and neck squamous cell carcinomas GT Biopharma to participate in upcoming HC Wainwright investor and EHA medical meeting conference $26.7 million in cash, cash equivalents and short-term investments as of March 31, 2022, is expected to provide ample runway to fund operations into 2023.BRISBANE, Calif., May 16, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced first quarter fiscal 2022 results for the...

Douglas Dynamics Announces Virtual Investor Event on May 25, 2022

Written by Customer Service on May 16, 2022. Posted in Public Companies.

MILWAUKEE, Wis., May 16, 2022 (GLOBE NEWSWIRE) — Douglas Dynamics, Inc. (NYSE: PLOW), North America’s premier manufacturer and upfitter of work truck attachments and equipment, today announced that it will host a virtual investor event on Wednesday, May 25th, 2022, via live webcast.Time: 10:30 a.m. Eastern (Lasting ~45 minutes) Title: Evolving demand creating opportunities for Work Truck Attachments Content: Roadmap for organic growth opportunities, and exclusive product video and interviews with truck equipment dealers from the 2022 NTEA Work Truck Show Format: Brief presentations and videos (~30 minutes), followed by Q&A session (~15 minutes) Hosts: Bob McCormick, President and Chief Executive Officer Sarah Lauber, Chief Financial Officer Mark Van Genderen, President, Commercial...

Humacyte to Present at the H.C. Wainwright Global Investment Conference

Written by Customer Service on May 16, 2022. Posted in Public Companies.

DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Dale Sander, Chief Financial Officer, and Heather Prichard, Ph.D., Chief Operating Officer, will deliver a corporate presentation in-person at the H.C. Wainwright Global Investment Conference taking place both virtually and in-person at the Fontainebleau Hotel in Miami, on May 24, 2022, at 10:30 a.m. ET. The webcast will be available for replay for at least 30 days following the presentation at https://investors.humacyte.com/news-events/events-and-presentations. About HumacyteHumacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered...

Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference

Written by Customer Service on May 16, 2022. Posted in Public Companies.

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference. The conference will be held in-person and virtually from May 23-26, 2022, with in-person participation held at the Fountainebleau Miami Beach Hotel in Miami Beach, Florida. Ms. Johnson’s virtual fireside chat will be available on-demand at https://journey.ct.events/view/2fa53f81-bd7f-404e-ad1b-20ea02738d5b and under “Presentations, Events & Webcasts” in the Investors section of the company’s website at http://ir.darebioscience.com, beginning at 7:00 a.m. Eastern Time on May 24, 2022. Following the conclusion of the...

RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus

Written by Customer Service on May 16, 2022. Posted in Public Companies.

Glen Rock, N.J., May 16, 2022 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that scientists associated with the Company have published a manuscript that raises the hope of novel treatments for tinnitus, the perception of sound in the absence of external auditory stimulation. Tinnitus is highly prevalent, with 10-15% of the general population worldwide affected, a statistic that can double in the elderly. The disorder can be markedly debilitating and is associated with and likely causal of anxiety, irritability, depression, sleep loss, social isolation, and suicidal ideation. While there are no treatments that demonstrate...

Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- – Reported positive safety data on SYN-020 intestinal alkaline phosphatase from the Phase 1 Multiple Ascending Dose clinical trial- -Formed Scientific Advisory Board and strengthened the leadership team to support transformative clinical development strategy and extension into oncology – -As of March 31, 2022, Synthetic Biologics reports $56.7 million in cash, which is expected to provide runway through the end of 2023- -Conference call and webcast to be held today at 8:30 a.m. ET- ROCKVILLE, Md., May 16, 2022 (GLOBE NEWSWIRE) —...

Reliance Global Group Achieves 82% Increase in Revenue for the First Quarter of 2022

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

Continues Successful Execution of Growth Strategy through Key Acquisitions and Senior Management Appointments LAKEWOOD, NJ, May 16, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Reliance Global Group, Inc. (Nasdaq: RELI; RELIW) (“Reliance”, “we” or the “Company”), which combines artificial intelligence (AI) and cloud-based technologies with the personalized experience of a traditional insurance agency, provided a business update today and reported financial results for the first quarter ended March 31, 2022. Ezra Beyman, CEO of Reliance Global Group, commented, “We continue to execute on our business growth strategy, as evidenced by an 82% increase in revenue to $4.2 million for the first quarter of 2022. This growth is a direct result of our successful acquisition strategy, including J.P. Kush last year and the Medigap Health Insurance...

Month: May 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals